D&D Pharmatech (347850)’in fiyatı nedir?

D&D Pharmatech (347850)’in fiyatı $38.45’dir

D&D Pharmatech (347850)’in piyasa değeri nedir?

D&D Pharmatech (347850)’in piyasa değeri $1.68B’dir.

D&D Pharmatech (347850) Kazanç

Established in 2014 and headquartered in Seongnam-si, South Korea, D&D Pharmatech Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing pharmaceutical treatments in both South Korea and the United States. The company's robust drug pipeline includes several candidates currently in clinical development: Phase II Trials: NLY01-PD, NLY01-AD, and NLY01-D are being investigated for their efficacy against Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively. Completed Phase IIa Trial: P4M01 has successfully finished its Phase IIa study for the treatment of periodontal disease. Phase I Trials: A significant portion of its portfolio is in early human trials, encompassing DD01 for obesity, diabetes, and nonalcoholic steatohepatitis (NASH); TLY012, targeting NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03, focused on Parkinson's disease, Alzheimer's disease, and neuroinflammation; PMI04, addressing Parkinson's disease, Alzheimer's disease, ALS, and depression; and PMI05 and PMI06, both exploring applications in oncology and immuno-oncology. Beyond the clinical stage, D&D Pharmatech is actively developing a range of preclinical compounds. These include NLY03 for stroke and Parkinson's disease; DD03 for obesity and NASH; TLY014, designed to modulate the tumor microenvironment; PMI31 for various cancer types; and VT01 for Parkinson's disease. Further research involves NLY02 for Parkinson's and Alzheimer's diseases; NLY12 for type 2 diabetes and obesity; DD02 for type 2 diabetes; PMI21 for prostate cancer; and PMI07 for oncology and fibrotic conditions. Additionally, the company strategically applies big data analytics to enhance its central nervous system drug research and diagnostics initiatives.

Yıl	Kazanç	Değiştir
Sağlanan tarihler için yeterli veri yok.

Yıl

Kazanç

Değiştir

Sağlanan tarihler için yeterli veri yok.

Şirket	Kazanç	Kazanç Farkı	Ülke
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

Şirket

Kazanç

Kazanç Farkı

Ülke